Concord Drugs Ltd
company logo

Concord Drugs Ltd

Concord Drugs Share Price

Pharmaceuticals
Small Cap

-

0 (0%)

Start Investing in Concord Drugs Ltd

*By signing up you agree to our Terms and Conditions

Concord Drugs Ltd Performance

-

-

-

-


-

-

-

-

-

Concord Drugs Ltd Fundamentals

33.74Cr

0

1

0.53

0.01

0%

33.82

i buttonClick here to know more about Fundamentals

Concord Drugs Ltd Financials

Concord Drugs Ltd Financialsright-arrow

Concord Drugs Ltd Shareholding Pattern

Concord Drugs Ltd Delivery and Volume

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready

S Nagi Reddy

1995

-

NameDesignation
S Nagi ReddyChairman & Managing Director
K Ramchandra ReddyIndependent Director
Koni ReddyWhole Time Director & CFO
S. Nagavenkata HareeshIndependent Director
S. Manoj Kumar ReddyWhole-time Director
Summela KasuIndependent Director
Namratha NaglaCompany Sec. & Compli. Officer
News and Events...

Similar Stocks

What's Trending

View All
View All

Concord Drugs Ltd FAQs

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Concord Drugs Ltd shares in BlinkX.
The share price of any stock is volatile and changes during the day due to a variety of variables. Concord Drugs Ltd's share price is ₹33.74 as of 2024-10-28.
Concord Drugs Ltd's P/E ratio is - times as of 2024-10-28.
Concord Drugs Ltd's most recent financial reports indicate a price-to-book ratio of 1, showing the company's stock market valuation in relation to the value of its real assets.
Market capitalization, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Concord Drugs Ltd's market capitalization is ₹33.74 Cr as on 2024-10-28.
The current financial records of Concord Drugs Ltd show a 1.28% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.
According to Concord Drugs Ltd's most recent financial filings, the company has a total asset value of ₹41.38, which includes current and non-current assets such as inventory, cash, properties, and equipment.
The 52-week high/low price of a Concord Drugs Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Concord Drugs Ltd's 52-week high and low as of 2024-10-28 are ₹35.51 and ₹33, respectively.